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Edited by Robert B. RussellAbstract Arguably, Alzheimer’s disease (AD) is a multifacto-
rial syndrome, rather than single disease, arising from a complex
array of neurochemical factors. Numerous studies on the molec-
ular pathogenesis of AD implicate a diversity of factors ranging
from neurotoxic peptides (b-amyloid) to inﬂammatory processes
(interleukins), but all culminating in a common neuropathology.
This diversity of molecular causation is an impediment to the de-
sign of eﬀective therapies for AD. To address this design prob-
lem, we sought to identify a single, common motif (a ‘‘common
receptor’’) shared by multiple structurally and functionally di-
verse proteins implicated in AD. This search revealed the pres-
ence of a common BBXB peptide motif and upon reﬁnement,
an AXBBXB motif; these regions can be exploited for the design
of a ‘‘promiscuous drug’’ that exploits a ‘‘one-drug-multiple-
receptors’’ therapeutic strategy for AD.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Characterized by amyloid plaques, neuroﬁbrillary tangles,
inﬂammatory intermediates and reactive oxygen species, Alz-
heimers disease (AD) inﬂicts neurotoxicity via a diverse array
of pathways. Regrettably, this complex molecular pathogene-
sis has impeded the design of eﬀective therapies for AD. To
date, drug design for AD has tended to focus on just one as-
pect of the neurotoxic cascade. While this highly focused ap-
proach has traditionally been the most successful strategy for
drug design, it may not be optimal for AD. Since AD is a com-
plex syndrome rather than a well-deﬁned disease, it may re-
quire a diﬀerent conceptual approach for purposes of drug
design.
The post-genomics biology era is providing paradigm chang-
ing evidence that the time-honoured single-drug-single-target
philosophy of rational drug design has fundamental concep-
tual limitations. There may be a need to address multiple tar-
gets simultaneously in order to achieve superior eﬃcacy for a
number of disease states. One such example is the notion of*Corresponding author. Fax: +1 902 494 1310.
E-mail address: donald.weaver@dal.ca (D.F. Weaver).
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doi:10.1016/j.febslet.2005.01.019one-drug-multiple-receptor therapeutics in cancer chemother-
apy as a means of thwarting drug resistance (e.g., targeting
tyrosine kinases) [1]. As presented in this study, there is evi-
dence that a similar strategy may have utility in the treatment
of AD.
In pursuing this design strategy, we sought to identify a sin-
gle, common motif (a ‘‘common receptor’’) shared by multiple
structurally and functionally diverse macromolecules impli-
cated in AD. This common receptor could then be exploited
for the design of a ‘‘promiscuous drug’’, thereby enabling a
‘‘one-drug-multiple-receptors’’ therapeutic strategy for AD.
This strategy has been achieved using a two-part approach:
Part A, uses alignment and molecular mechanics calculations
to identify a common receptor motif among 43 diverse pro-
teins involved in the molecular pathogenesis of AD; Part B,
uses molecular mechanics calculations to ascertain whether
the identiﬁed common receptor motif of Part A is merely a
coincidental observation or provides fundamental insight into
the molecular pathogenesis of AD.2. Materials and methods
2.1. PDB data collection
Based upon the principal theories for AD (e.g., amyloid, tau, ApoE,
and neuroinﬂammation-based hypotheses) a list of 43 diﬀerent AD-
associated proteins was compiled; their primary and secondary struc-
tures were obtained from the RCSB Protein Data Bank. The following
ﬁve-step strategy was then devised and implemented to search these di-
verse proteins for the presence of a single, common receptor motif:
Step 1 – searching for a common tetrapeptide or hexapeptide motif:
Collectively, current central nervous system (CNS) drugs have an aver-
age molecular weight of 312 g/mol and contain an average of 43 atoms
[2]. Our own molecular mechanics geometry optimizations (MM2
Force Field, Newton–Raphson second derivative minimization
scheme) of 30 randomly selected representative neuroactive molecules
(anticonvulsants, antidepressants, antipsychotics) identiﬁed a greatest
dimension value ranging from 6.5 to 9.4 A˚, e.g., the carbon-based skel-
eton of the anticonvulsant carbamazepine has a maximal expanse of
8.4 A˚ between functionalities on its furthest points. Since a hexapep-
tide spans approximately 10 A˚, depending upon conformation, it pro-
vides a receptor zone suﬃciently large to bind a CNS drug. To
accommodate the lower end of neuroactive drug molecule size, the
lower limit of this search was set at a tetrapeptide. (Step 1 considers
only amino acids arranged contiguously in primary amino acid se-
quence and does not consider residues that are widely separated in
terms of primary structure but geometrically close in terms of tertiary
structure.)
Step 2 – searching for a motif with equivalent, not necessarily identical
residues: In accordance with other alignment scoring processes [3], res-
idues were grouped into categories of equivalence; i.e., positively
charged residues (Lys, His, and Arg) may be equivalent for purposes
of drug design.blished by Elsevier B.V. All rights reserved.
Table 1
A summary of BBXB receptors in AD-implicated proteins
Proteina BBXB 2 structure AXBBXB
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directions: From the perspective of a drug molecule (and disregarding
both backbone contributions and tertiary structure considerations), a
sequence of amino acid side chains is essentially equivalent when read
in either direction i.e., the amino acid sequence A-B-C is equivalent to
C-B-A when viewed from the perspective of an incoming molecule.
Step 4 – searching for a motif with solvent/drug accessibility: Since a
region buried deep within a protein is not ‘‘druggable’’, sequences on
the surfaces of proteins were regarded with priority. This criterion
skews the search in favour of polar residues that normally coat the sur-
face of a globular protein.
Step 5 – searching for a motif in a bioactive region of the protein: A
priority was assigned to peptide segments located within the known ac-
tive sites of the 43 proteins under study.
2.2. Computational evaluation
Alignments of the common motifs were performed using the maxi-
mum common subgraph component of the Cerius2 Align algorithm
[4]. This algorithm aligns molecules according to the positions of spec-
iﬁed atoms.Ab HHQK Helix EVHHQK
Taub KKAK DDKKAK
S100b HKLK Random DKHKLK
KLKK Random
C1qA KKGH Sheet DPKKGH
IFN-c KKKR Helix KKKRDD
KRKR Random
AChE RFRR Random RFRRPEd
ApoE4 RKLR Helix
KLRK Helix
HLRK Helix
IL-1R1 HKEK Sheet/turn
HQHK Sheet
IL-1bCE KKAH Random
RKVR Helix
IL3 HHLK Pt helix
HLKR Pt helix
IL4 HHEK Helix
HRHK Helix
IL6 KKAK Pt helix EGKKMR
KAKR Random
KKMR Random
IL10 KKVK Sheet
KVHK Sheet
HRVK Helix
IL12 HKLK Sheet/turn
KREK Random
KKDR Random
KSKR Random
REKK Random
IL13 HLKK Helix
a1-ACT KRWR Helix
BHMT RARK Random
B7-1 KREH Sheet
ICAM-1 RRDH Pt. Helix3. Results and discussion
3.1. Common BBXB receptor
Initially, the ﬁve-step strategy was used to identify a com-
mon tetrapeptide segment among the 43 AD-associated pro-
teins. This revealed a BBXB sequence (where B is a basic
residue and X is any other amino acid) common to 27 of the
43 proteins. This sequence is palindromic in terms of drug
interactions (see Step 3) and thus BXBB regions were consid-
ered equivalent. Some proteins contained more than one re-
gion, accounting for a total of 46 BBXB/BXBB motifs: 38%
were in a helical conformation, 20% in a sheet conformation,
and 42% in a random coil form. The tau protein had no avail-
able PDB ﬁle and therefore remains unclassiﬁed in terms of
secondary structure. All BBXB motifs (except in the HFE
and MHC CII proteins) were in solvent-accessible regions. In
general, the BBXB motifs were contained within the bioactive
portion of the proteins; e.g., the BBXB regions of b-amyloid,
S100b, C1qA, IL6 and ApoE4 are all central to their biological
activity [16–18].
To deduce the suitability of the BBXB motif for drug design,
the various protein domains containing the BBXB motifs were
aligned computationally using the maximum common sub-
graph component of the Cerius2 Align algorithm. This re-
vealed a common basic residue triangle (Fig. 1). The
standard deviations for the relative positions of the positively
charged atoms (also given in Fig. 1) lie within a reasonable res-Fig. 1. The common BBXB receptor triangle from the superposition
of 46 BBXB motifs obtained from 27 AD-associated proteins.idue ﬂexibility zone to allow for interaction with a common
drug molecule. This is not to suggest that a single drug mole-
cule be designed to interact with all 27 common receptors,
however, it is conceivable that any subset of proteins chosen
would provide a reasonable target through which to create
an even more speciﬁc common drug interaction.
3.2. Common AXBBXB receptor
To further enhance the uniqueness and complexity of the
BBXB motif, the proteins were next searched for a common
hexapeptide motif. The previously identiﬁed BBXB region
was extended to an AXBBXB motif, where A refers to an
acidic residue. Eight proteins were found to contain this regionRDHH Pt. Helix
MIP-1a KRSR Random
MIP-1b KRSK Random
SDF-1 KHLK Sheet
Neprilysin RGKK Random
Transferrin KKLR Random
HCRK Random
KKCR Random
RANTES RKNR Random
HFE HKIRc Pt. Helix ERHKIRc
MHC(CII) RKFHc Sheet
aAlso examined were TNF-a, NGF, ERAB, SAP, C1qB, C1qC, IFN-c
receptor, CD40, IL-1a, IL-1b, IL-2, IL-8, MCP-1, IDE, a-2-macro-
globulin and NO2 synthase. References for protein–AD links – see
Refs. [5–15].
bNo PDB ﬁle available.
cBuried too deep for a reasonable drug interaction – was not included
in receptor evaluation.
dNeglected from receptor analysis as a statistical outlier.
Fig. 2. The common AXBBXB receptor obtained from the superpo-
sition of ﬁve diﬀerent AD-associated proteins.
Fig. 3. Promiscuous binding of heparin with (A) RANTES, (B) Ab,
and (C) C1qA.
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studied for their links to AD (HFE to a lesser degree). Such a
commonality suggests the possibility of designing a more spe-
ciﬁc therapeutic, selective to this common target, yet promiscu-
ous within this subset of proteins (Fig. 2).
3.3. Potential mechanistic signiﬁcance of common receptor
The presence of this BBXB region in multiple molecular cul-
prits implicated in AD suggests that the existence of this cat-
ionic tetramer may not be merely coincidental. A large class
of proteins, collectively known as heparin/heparan sulfate
(HS)-binders, has been found to contain this region, which
claims responsibility for its binding. Heparins and HSs are sac-
charide polymers. The varying degrees of sulfonation, as well
as functional group substitutions throughout the polymer, aids
in deﬁning the molecules speciﬁcity. The ability of b-amyloid
to form neurotoxic aggregates is mediated through the interac-
tion of its BBXB domain (HHQK) with HS and related glucos-
aminoglycans (GAGs) in the neuronal membrane [19–21].
Likewise, multiple inﬂammatory chemokines involved in AD
(RANTES, MIP-1a, and MIP-1b) also interact with neurons
via interactions between their BBXB motifs and HSPG
[22,23]. To further scrutinize the feasibility of a single promis-
cuous drug (functioning as an HSPG-mimetic) to bind multi-
ple receptors, we computationally evaluated heparin – a
well-described GAG – for its ability to bind the common motif
of the various proteins (Fig. 3).
To simulate the HSPG–BBXB interaction, a polysulfonated
disaccharide fragment of heparin was used to model the GAG.
Binding simulations were performed using the CHARMM
force ﬁeld as implemented in QUANTA [24]. In these simula-
tions, the full protein was modeled and all atoms within the
HSPG–BBXB interaction region were explicitly optimized.
Solvation eﬀects were included using a sphere of radius 15 A˚
TIP3 water molecules centered on the central atom of the hex-
amer/tetramer commonality.Interaction energies, Eint, were computed using the following
equation:
Eint ¼ EHSPG–BBXB  EHSPG  EBBXB
where EHSPG–BBXB is the energy of the heparin–protein com-
plex, and EHSPG and EBBXB are the energies of the isolated
heparin and protein, respectively.
Given the strong electrostatic nature of the HSPG–BBXB
interaction, it is not surprising that the various BBXB-rich
proteins were able to bind to HSPG. However, the precise nat-
ure of this interaction varied from protein to protein as dem-
onstrated for RANTES, b-amyloid and C1qA.
RANTES, an experimentally demonstrated heparin binder,
forms six diﬀerent interactions between its BBXB common
receptor (RKNR) and the dimer heparin in silico – four elec-
trostatic and two hydrogen-bonding interactions. Arg44
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at bonding distances of 2.08 and 2.26 A˚, respectively; Lys45
interacted with a sulfonate and hydroxyl group at distances
of 1.68 and 1.70 A˚, respectively; and Arg47 interacted strongly
with two sulfonate groups residing on the sugar bonding at dis-
tances of 2.24/2.40, 1.77/1.96 A˚ (Fig. 3). Overall, these interac-
tions gave a total binding energy of 847 kcal/mol.
b-Amyloid was also evaluated in the same manner. It gave a
binding energy for the Ab-heparin complex of 447 kcal/mol.
This accounted for two electrostatic and two hydrogen-bond-
ing interactions with the HHQK region, as well as two interac-
tions with the backbone of the helical structure. Both His13
and Lys16 formed interactions with sulfonate groups on the
same side of the dimer giving bonding distances of 1.96 and
1.96/2.26 A˚, respectively. The remaining His in the receptor
formed two hydrogen bonds with the pyranose oxygen and a
terminal hydroxyl group at distances of 2.03 and 1.78 A˚,
respectively.
Finally, C1qA also showed favourable binding with the
disaccharide heparin fragment. Lys201 formed the strongest
electrostatic interaction at 1.63 A˚, while Lys200 and His203
had long range electrostatic interactions with the sulfonates
at 3.05 and 3.48 A˚, respectively. The heparin sugar dimer also
formed a hydrogen bond with the receptors backbone struc-
ture. Overall, this complex gave a binding energy of
563 kcal/mol.
These results strongly support the potential for a common
BBXB region present in numerous AD-associated macromole-
cules to eﬀectively bind the same HSPG substrate. This further
strengthens the concept of a single drug-like HSPG-mimetic
molecule with promiscuous BBXB-binding capabilities.3.4. Preliminary screen of non-AD-related proteins
To address the issue of receptor speciﬁcity and to evaluate
the possibility of the coincidental occurrence of a BBXB/
BXBB region in other proteins, 40 non-AD-related proteins
were selected for analysis. We randomly selected 40 proteins,
involved in heart, liver, or kidney function, from the RCSB
Protein Databank. A list of these proteins can be found in
the supplementary data section. Of the 40 proteins examined,
19 contained at least one BBXB/BXBB region (48%). This
same set was re-examined for AXBBXB regions; only 4
(10%) were found to contain this receptor. Thus for purposes
of speciﬁcity in drug design, the AXBBXB motif oﬀers greater
speciﬁcity.4. Concluding remarks
The novel concept of a promiscuous drug addresses the
emerging need for one-drug-multiple-target therapeutics. A
promiscuous drug candidate is not a collection of diﬀerent
drug molecules combined in a single pill to act on a multitude
of receptors implicated in the pathogenesis of a single disease;
rather, it is a single entity that occupies speciﬁc and discrete
volumes of biological space common to multiple diﬀerent
receptor targets. Given its complex multifactorial etiology, it
is highly probable that AD may beneﬁt from such a promiscu-
ous drug strategy. The BBXB and AXBBXB motifs identiﬁed
in this study represent targets worthy of promiscuous drug
design.In addition to providing an enabling strategy for promiscu-
ous drug design, this unbiased computer-driven identiﬁcation
of the BBXB/AXBBXB motifs may also provide fundamental
insights into the biochemical basis of AD. The eﬀective binding
of the GAG, heparin, to the identiﬁed domains in 27 Alzhei-
mers-associated proteins also strengthens the design possibili-
ties for promiscuous drug therapeutics, as well as providing a
harmonized structural basis for understanding and combating
the immunopathology of AD.
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